Pharmacogenetic biomarker factory: how does it work?
Abstract
Despite the strides made in the study of -omics data, including pharmacogenomic data, there is still a lack of reliable, reproducible, sensitive, specific and, most importantly, clinically useful biomarkers for predicting response to drug treatment in real clinical practice. An important impact in the development and implementation of new pharmacogenetic biomarkers can be made by the creation of an appropriate ecosystem around biomarkers by uniting capacities of academic and research centers, biomedical laboratories and pharmaceutical companies, IT and artificial intelligence companies into consortiums. The article provides an overview of the so-called “biomarker factory”, which allows to build and systematize the process of introducing a pharmacogenomic biomarker into clinical practice.
About the Authors
D. A. Sychev
Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Sychev Dmitry A., MD, PhD, Professor, Professor of the Russian Academy of Sciences (RAS), Corresponding Member of RAS, Head of B. E. Votchal Department of Clinical Pharmacology and Therapy
Moscow
K. V. Mirzaev
Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Mirzaev Karin B., MD, PhD, Assistant Professor of B. E. Votchal Department of Clinical Pharmacology and Therapy, Head of Adverse Drug Reactions Genomic Predictors Research Laboratory in Research Institute of Molecular and Personalized Medicine
Moscow
N. P. Denisenko
Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Denisenko Natalia P., MD, PhD, Assistant Professor of B. E. Votchal Department of Clinical Pharmacology and Therapy, Head of the Department of Personalized Medicine in Research Institute of Molecular and Personalized Medicine
st. Barrikadnaya, 2/1, str. 1, Moscow, Russia, 125993
S. P. Abdullaev
Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Abdullaev Sherzod P., PhD (Biol.), Head of the Department of Molecular Medicine in Research Institute of Molecular and Personalized Medicine
st. Barrikadnaya, 2/1, str. 1, Moscow, Russia, 125993
E. A. Grishina
Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Grishina Elena A., PhD (Biol.), Assistant Professor, Director of the Research Institute of Molecular and Personalized Medicine
st. Barrikadnaya, 2/1, str. 1, Moscow, Russia, 125993
References
1. Order of the Ministry of Health of Russia dated 01.02.2019 No. 42 (revised from 24.08.2020) “On approval of the departmental program” Development of fundamental, translational and personalized medicine”. https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/042/771/original/Приказ_№_42_ВЦП. pdf?1549880974 (12 September 2021). In Russian
2. Decree of the Government of Russia dated May 21, 2013 No. 426 “On the federal target program” Research and development in priority areas of development of the scientific and technological complex of Russia for 2014-2021”. https://fcpir.ru/business/prioritety-nauchnotekhnologicheskogo-razvitiya/ (12 September 2021). In Russian [Постановление Правительства России от 21 мая 2013 г. № 426 «О федеральной целевой программе «Исследования и разработки по приоритетным направлениям развития научно-технологического комплекса России на 2014-2021 годы». https://fcpir.ru/business/prioritety-nauchno-tekhnologicheskogorazvitiya/ (12.09.2021)].
3. The precision medicine initiative. https://obamawhitehouse.archives.gov/precision-medicine (13 September 2021).
4. The 100,000 Genomes Project. https://www.genomicsengland.co.uk/about-genomics-england/the-100000-genomes-project (13 September 2021).
5. Health research and innovation of European Commission. Personalised medicine. https://ec.europa.eu/info/research-and-innovation/research-area/healthresearch-and-innovation/personalised-medicine_en (13 September 2021).
6. The project Clinical Implementation of Personalized Medicine in Health Services (Personalized Medicine Applied-MedeA). https://www.proyectomedea.es/en/home/ (13 September 2021).
7. Sychev DA. Applied pharmacogenetics. Tver: Izdatel’stvo Triada, 2021. p. 496. In Russian
8. Whitcomb DC. Barriers and research priorities for implementing precision medicine. Pancreas. 2019;48(10):1246-1249. DOI: 10.1097/MPA.0000000000001415.
9. BEST (Biomarkers, EndpointS, and other Tools) Resource. https://www.ncbi.nlm.nih.gov/books/NBK326791/ (14 September 2021).
10. Davis KD, Aghaeepour N, Ahn AH, et al. Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities. Nat Rev Neurol. 2020;16(7):381–400. DOI: 10.1038/s41582-020-0362-2.
11. Silva PJ, Schaibley VM, Ramos KS. Academic medical centers as innovation ecosystems to address population — omics challenges in precision medicine. J Transl Med. 2018;16(1):28. DOI: 10.1186/s12967-018-1401-2.
12. Vandenbroeck K, Comabella M, Tolosa E, et al. United Europeans for development of pharmacogenomics in multiple sclerosis network. Pharmacogenomics. 2009;10(5):885-894. DOI: 10.2217/pgs.09.33.
13. Sobocki P, Pugliatti M, Lauer K, et al. Estimation of the cost of MS in Europe: extrapolations from a multinational cost study. Mult Scler. 2007;13(8):1054–1064. DOI: 10.1177/1352458507077941.
14. Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes Project (U-BIOPRED). https://europeanlung.org/en/projects-and-campaigns/past-projects/u-biopred (14 September 2021).
15. Craig BM, Han G, Munkin MK, et al. Simulating the contribution of a biospecimen and clinical data repository in a phase II clinical trial: a value of information analysis. Statistical methods in medical research. 2016;25(4):1303–1312. DOI: 10.1177/0962280213480282.
16. Consortium “Genetics of Cardiovascular Diseases”. https://cardiogenetics.ru (14 September 2021). In Russian
Review
For citations:
Sychev D.A., Mirzaev K.V., Denisenko N.P., Abdullaev S.P., Grishina E.A. Pharmacogenetic biomarker factory: how does it work? Russian Journal for Personalized Medicine. 2021;1(1):33-42. https://doi.org/615.1
Views:
356
Email this article 